7,116 Intuitive Surgical, Inc. $ISRG Shares Sold by Oppenheimer & Co. Inc.

Key Points

• Oppenheimer reduced its Intuitive Surgical stake by 37.4% in the third quarter, selling 7,116 shares and retaining 11,902 shares valued at approximately $4.84 million.
• Despite the reduction, institutional ownership remains high at 83.64%, while several major investors increased their positions. Analysts maintain a favorable outlook, with a consensus “Moderate Buy” rating and an average price target of $493.54.
• Intuitive Surgical reported strong quarterly results, including $3.05 billion in revenue and $3.00 in EPS, beating estimates and marking 21.7% year-over-year revenue growth. However, premium valuation, margin pressure and recent insider selling remain potential concerns.

Oppenheimer & Co. Inc. lessened its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 37.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,902 shares of the medical equipment provider's stock after selling 7,116 shares during the quarter. Oppenheimer & Co. Inc.'s holdings in Intuitive Surgical were worth $4,840,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in ISRG. Bank of New York Mellon Corp purchased a new position in shares of Intuitive Surgical during the 2nd quarter valued at $1,335,753,000. Arrowstreet Capital Limited Partnership raised its holdings in shares of Intuitive Surgical by 95.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider's stock worth $970,635,000 after acquiring an additional 1,027,475 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Intuitive Surgical by 55.8% during the third quarter. Assenagon Asset Management S.A. now owns 1,557,940 shares of the medical equipment provider's stock worth $633,505,000 after acquiring an additional 558,099 shares in the last quarter. Amundi boosted its position in Intuitive Surgical by 8.6% during the first quarter. Amundi now owns 2,428,356 shares of the medical equipment provider's stock valued at $1,119,448,000 after purchasing an additional 193,096 shares during the last quarter. Finally, Temasek Holdings Private Ltd boosted its position in Intuitive Surgical by 416.4% during the first quarter. Temasek Holdings Private Ltd now owns 227,211 shares of the medical equipment provider's stock valued at $104,742,000 after purchasing an additional 183,211 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ISRG shares. Zacks Research upgraded Intuitive Surgical from a "hold" rating to a "strong-buy" rating in a research note on Thursday, October 22nd. BMO Capital Markets reiterated an "outperform" rating on shares of Intuitive Surgical in a report on Monday, July 20th. UBS Group reiterated a "buy" rating on shares of Intuitive Surgical in a report on Tuesday, October 13th. Weiss Ratings reissued a "hold (c)" rating on shares of Intuitive Surgical in a research note on Friday, August 14th. Finally, Leerink Partners set a $503.00 price objective on Intuitive Surgical and gave the stock an "outperform" rating in a report on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Intuitive Surgical has a consensus rating of "Moderate Buy" and an average price target of $493.54.

Insiders Place Their Bets

In related news, Director Gary Guthart sold 20,095 shares of Intuitive Surgical stock in a transaction on Friday, October 23rd. The shares were sold at an average price of $451.61, for a total value of $9,075,102.95. Following the transaction, the director owned 1,204,530 shares in the company, valued at $543,977,793.30. This trade represents a 1.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Wadors sold 1,078 shares of the business's stock in a transaction on Friday, October 23rd. The stock was sold at an average price of $443.80, for a total transaction of $478,416.40. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 38,778 shares of company stock worth $16,814,967 in the last ninety days. 0.60% of the stock is owned by insiders.

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive Surgical reported quarterly revenue of $3.05 billion, above the $2.91 billion consensus estimate, and earnings of $3.00 per share versus expectations of $2.65. The earnings beat supports the long-term growth outlook for its robotic-surgery platforms. ISRG Sales Growth Article
• Positive Sentiment: Analyst sentiment remains favorable. ISRG carries a “Moderate Buy” consensus rating, with an average price target of $493.54; Baird raised its target to $550 and maintained an outperform rating, while other firms reiterated bullish views.
• Positive Sentiment: Institutional ownership is high at 83.64%, and several large investors—including Bank of America, Amundi, Arrowstreet Capital and Janus Henderson—recently increased their positions, providing a supportive ownership backdrop.
• Neutral Sentiment: Investors are weighing whether ISRG’s premium valuation is justified. The stock has rebounded over the past one to three months but remains below its prior-year level, leaving the sustainability of procedure growth and earnings estimates as key issues.
• Negative Sentiment: Profitability remains a concern: commentary pointed to lower net income and earnings per share despite higher revenue, indicating margin pressure. With the shares trading at a high earnings multiple, any slowdown in procedures, pricing or margins could create volatility.
• Negative Sentiment: Several insiders reported sales, including former CEO Gary Guthart, Fredrik Widman and EVP Mark Brosius. Brosius sold shares in two transactions, while Guthart’s sale was substantially larger. The trades were conducted under pre-arranged Rule 10b5-1 plans, reducing their signaling value, but the selling may weigh modestly on sentiment. ISRG Insider Sales

Intuitive Surgical Trading Up 1.0%

ISRG stock opened at $448.76 on Friday. The firm has a market cap of $155.56 billion, a PE ratio of 54.26, a PEG ratio of 3.06 and a beta of 1.46. Intuitive Surgical, Inc. has a 1 year low of $328.57 and a 1 year high of $603.88. The company has a fifty day simple moving average of $400.39 and a 200 day simple moving average of $434.76.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 EPS for the quarter, topping the consensus estimate of $2.65 by $0.35. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The firm had revenue of $3.05 billion for the quarter, compared to the consensus estimate of $2.91 billion. During the same period in the prior year, the business posted $2.40 earnings per share. The business's quarterly revenue was up 21.7% on a year-over-year basis. As a group, analysts forecast that Intuitive Surgical, Inc. will post 9.37 EPS for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company's primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.